Directory › Eurofins BioPharma Product Testing

Eurofins BioPharma Product Testing — Glostrup

Glostrup, Denmark · Testing lab

This is a record of what regulators published, not a rating.

Site facts

Company
Eurofins BioPharma Product Testing
Name(s) in FDA data
Eurofins Biopharma Product Testing, Denmark A/S
FEI number(s)
3006272083 (present in FDA Data Dashboard records for this name and city)
Location (as in FDA data)
Glostrup, Denmark
Records matched
5 FDA inspections · 1 inspection with posted 483 citations
Most recent FDA inspection in dataset
17 May 2023 — NAI

Capabilities (from the company's website)

  • Analytical testing
    …and NAT Small molecules Supporting your facility Services that span risk identification, method development, sampling, analytical validation, and ongoing monitoring Disinfectant validation ensures…
  • Microbiology
    …agents are fit for purpose and that your facility is safe for production. A full suite of environmental monitoring services designed to be as rigorous, responsive, and reliable as your cleanroom demands.…

Taken from a company-level page; the company does not publish a separate page for this site, so tags may describe the wider organisation. Source: https://www.eurofins.com/en/biopharma-services/biopharma-product-testing/, checked 16 Oct 2026. Quoted text shows the wording each tag is based on.

Regulatory timeline

Newest first. Each entry links to the published source. Inspection classifications: NAI = no action indicated, VAI = voluntary action indicated, OAI = official action indicated (FDA definitions). Posted 483 citations are FDA's short summaries, not the full Form 483.

  1. 17 May 2023
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3006272083, inspection ID 1222906)

  2. 22 Jun 2016
    Form 483 observations 5 posted Form 483 citation(s)

    Citation summaries (5)
    • 21 CFR 211.160(a): Deviations from laboratory control requirements
    • 21 CFR 211.160(b): Scientifically sound laboratory controls
    • 21 CFR 211.194(a): Complete test data included in records
    • 21 CFR 211.22(d): Procedures not in writing, fully followed
    • 21 CFR 211.68(b): Computer control of master formula records

    Source: FDA Data Dashboard – Citations (FEI 3006272083, inspection ID 976102)

  3. 22 Jun 2016
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3006272083, inspection ID 976102)

  4. 14 Dec 2012
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3006272083, inspection ID 811362)

  5. 30 Mar 2012
    FDA inspection FDA inspection classified NAI

    No Action Indicated (NAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3006272083, inspection ID 780431)

  6. 12 May 2009
    FDA inspection FDA inspection classified VAI

    Voluntary Action Indicated (VAI). Product type(s): Drugs. Project area(s): Drug Quality Assurance.

    Source: FDA Data Dashboard – Inspections (FEI 3006272083, inspection ID 578807)

This is a record of what regulators published, not a rating. Absence of a record here does not mean no record exists; see methodology for what we check and how records are matched.